Benjamin F. Edwards & Company Inc. Raises Stock Position in Novo Nordisk A/S (NYSE:NVO)

Benjamin F. Edwards & Company Inc. increased its stake in Novo Nordisk A/S (NYSE:NVO) by 452.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,827 shares of the company’s stock after acquiring an additional 19,517 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Novo Nordisk A/S were worth $2,465,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Xponance Inc. bought a new stake in Novo Nordisk A/S during the 3rd quarter valued at $248,000. Stratos Wealth Partners LTD. lifted its holdings in shares of Novo Nordisk A/S by 228.9% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 17,857 shares of the company’s stock valued at $1,624,000 after purchasing an additional 12,427 shares during the last quarter. Stratos Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth about $237,000. Bank of New York Mellon Corp boosted its stake in Novo Nordisk A/S by 97.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 863,598 shares of the company’s stock worth $78,536,000 after purchasing an additional 425,392 shares in the last quarter. Finally, Bailard Inc. increased its stake in Novo Nordisk A/S by 104.7% during the 3rd quarter. Bailard Inc. now owns 8,191 shares of the company’s stock valued at $745,000 after purchasing an additional 4,189 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research reports. UBS Group began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Trading Down 0.8 %

NYSE NVO opened at $123.05 on Friday. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The firm’s fifty day moving average is $127.20 and its two-hundred day moving average is $112.93. The firm has a market cap of $552.19 billion, a PE ratio of 42.43, a P/E/G ratio of 2.06 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.